Antiemetic Guidelines
Several national and international guideline groups include EMEND as part of a standard antiemetic regimen for select patients.
The 2008 NCCN and MASCC antiemetic guidelines include fosaprepitant for Day 1 protection.
ASCO=American Society of Clinical Oncology; NCCN=National Comprehensive Cancer Network; ONS=Oncology Nursing Society;
MASCC=Multinational Association of Supportive Care in Cancer; AC=anthracycline+cyclophosphamide.
a
NCCN considers AC-based chemotherapy to be highly emetogenic.
b
NCCN also suggests that aprepitant should be given to select patients receiving other chemotherapies of moderate emetic risk
(eg. carboplatin, cisplatin, doxorubicin, epirubicin, ifosfamide, irinotecan, or methotrexate).
(eg. carboplatin, cisplatin, doxorubicin, epirubicin, ifosfamide, irinotecan, or methotrexate).
- References:1.Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24(18):2932–2947.
- 2.National Comprehensive Cancer Network. Clinical practice guidelines in oncology—v.3.2008: antiemesis. http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Published February 5, 2008. Accessed
July 16, 2008. - 3.Oncology Nursing Society. Putting Evidence Into Practice (PEP) Card. What interventions are effective in preventing and treating chemotherapy-induced nausea and vomiting (CINV)? ons.org/outcomes/pepcard/pdf/nausea-pepcard4-06.pdf. Accessed July 16, 2008.
- 4.Gralla RJ, Roila F, Tonato M. for Multinational Association of Supportive Care in Cancer. Perugia International Cancer Conference VII. Based on: the Consensus Conference on Antiemetic Therapy. mascc.org/media/Resource_centers/MASCC_Guidelines_Update.pdf. Updated March 2008. Accessed July 16, 2008.
Important Safety Information
EMEND and EMEND for Injection, in combination with other antiemetic agents, are indicated in adults for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin.
EMEND and EMEND for Injection have not been studied for treatment of established nausea and vomiting. Chronic continuous administration of EMEND or EMEND for Injection is not recommended.
Selected Important Safety Information
Before prescribing EMEND or EMEND for Injection, please read the Prescribing Information. The Patient Information also is available.
For information about Merck products or services, please call 866-448-7590. The Merck National Service Center will be pleased to assist you Monday through Friday from 8 AM to 7 PM ET.
PRIVACY POLICY